-
Mashup Score: 4EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function - 4 day(s) ago
Isshiki et al. demonstrate that EZH2 inhibitors re-activate immune synapse functions between B cell lymphomas and T cells, sensitizing lymphomas to T cell immunotherapies. EZH2 inhibition enhances killing activity by promoting T cell recruitment, prolonging binding and increasing contact surface with lymphoma cells, and prevents T cell exhaustion. This strategy is currently under clinical evaluation.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials - 4 day(s) ago
Patients with follicular lymphoma (FL) who progress within 24 months of front-line therapy (POD24) have poor outcomes, but clinical factors predicting earl
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials [Mar 17, 2022] Casulo et al. for the FLASH (Follicular Lymphoma Analysis of Surrogacy Hypothesis) Group @BloodJournal https://t.co/KFQ8MupK5C #lymsm… https://t.co/a3FTReX2cI https://t.co/7TKPEMbDSh
-
-
Mashup Score: 1POD24 in follicular lymphoma: time to be “wise” - 4 day(s) ago
This issue of Blood features valuable new data from Casulo et al1 focusing on an important problem in follicular lymphoma (FL). FL is the most common form
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
POD24 in follicular lymphoma: time to be “wise” [Mar 17, 2022] @JohnPLeonardMD https://t.co/jLMd14DCJZ #lymsm https://t.co/TyzoLiNI96
-
-
Mashup Score: 5
Background: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP
Source: papers.ssrn.comCategories: General Medicine News, Hem/OncsTweet-
Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial {Pre-print} [Nov 9, 2024] Hoffmann et al. @TheLancet https://t.co/Txy4v1GCRP #NCT05271929 #COVID19CP #COVID19
-
-
Mashup Score: 0
The urgent response to the COVID-19 pandemic has highlighted the importance of diverse, real-world data sources, such as electronic health records, insurance claims, and patient registries, to further inform evidence-based care amid an evolving public health crisis. Real-world data have the…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Time-Related Biases in Nonrandomized COVID-19–Era Studies Using Real-world Data [Jun 17, 2021] @gregcalip @RMiksad Sarkar @JAMAOnc https://t.co/lXZTYLYdfV #COVID19CP #COVID19nCancer #COVID19 #CCC19 @COVID19nCCC ...real-world data should continue to play a crucial role...
-
-
Mashup Score: 1Survival in Patients With Hematologic Cancers and COVID-19 - 4 day(s) ago
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc
-
-
Mashup Score: 7
Key PointsIn a statewide cohort, time to resolution of iron deficiency was 1.9 years, and 58% of patients did not achieve resolution within 3 years.Greater
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Iron deficiency resolution and time to resolution in an American health system [Nov 27, 2024] Cogan et al. @BloodAdvances https://t.co/ExzbvEJ2wh #anemia #hemetwitter https://t.co/YDEYBdhyTN
-
-
Mashup Score: 3
AdoMet at a daily dose of 800 mg for 4 weeks does not appear to significantly affect Hcy levels in the blood.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in humans: a DBRCT [2009] @mtmdphd @babmd Loehrer, Cha, Mandrekar, @AmitSoodMD Wahner-Roedler https://t.co/PGJfHRlzmG #NCT00284011 https://t.co/0s6SiL6TQp
-
-
Mashup Score: 2Tri-specific Antibody SAR442257 in RRMM and Non- Hodgkin Lymphoma | Fredrik Schjesvold | #ASH24 - 9 day(s) ago
Fredrik Schjesvold, MD, PhD, discusses a phase 1 trial of a trispecific drug designed to boost T-cell activation in myeloma and lymphoma treatment. While the…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
RT @MyelomaTeacher: Tri-specific Antibody SAR442257 in RRMM and Non- Hodgkin Lymphoma | Fred... https://t.co/EjecO5inCZ #MMsm #ASH24 #Healt…
-
-
Mashup Score: 5Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms - 10 day(s) ago
Leukemia – Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Whole-genome sequencing [WGS] of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms [Apr 9, 2018] Phuc H. Hoang et al. @LeukemiaJnl https://t.co/NFLnBKDVTw #mmsm #cagenome
-
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function [Dec 5, 2024] Isshiki et al. @Cancer_Cell https://t.co/AZBxgIAJ2y #lymsm #ImmunoOnc #CARTcell https://t.co/own9QX3wnD